365 related articles for article (PubMed ID: 32390595)
1. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions.
Liu TT; Li XF; Wang L; Yang JL
Cancer Biomark; 2020; 28(3):293-299. PubMed ID: 32390595
[TBL] [Abstract][Full Text] [Related]
2. [Breast calcifications with percutaneous vacuum-assisted biopsy diagnosis of malignancy or atypical hyerplasia: correlations with surgical findings].
Piubello Q; Montemezzi S; D'Atri C
Pathologica; 2002 Dec; 94(6):299-305. PubMed ID: 12540993
[TBL] [Abstract][Full Text] [Related]
3. Blurry boundaries: do epithelial borderline lesions of the breast and ductal carcinoma in situ have similar rates of subsequent invasive cancer?
Choi DX; Eaton AA; Olcese C; Patil S; Morrow M; Van Zee KJ
Ann Surg Oncol; 2013 Apr; 20(4):1302-10. PubMed ID: 23161115
[TBL] [Abstract][Full Text] [Related]
4. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
5. Type of Architecture, Presence of Punctate Necrosis, and Extent of Involvement in Atypical Ductal Hyperplasia Can Predict the Diagnosis of Breast Carcinoma on Excision: A Clinicopathologic Study of 143 Cases.
Zhang C; Wang EY; Liu F; Ruhul Quddus M; James Sung C
Int J Surg Pathol; 2021 Oct; 29(7):716-721. PubMed ID: 33881947
[TBL] [Abstract][Full Text] [Related]
6. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
7. Atypical ductal hyperplasia: Our experience in the management and long term clinical follow-up in 71 patients.
Latronico A; Nicosia L; Faggian A; Abbate F; Penco S; Bozzini A; Cannataci C; Mazzarol G; Cassano E
Breast; 2018 Feb; 37():1-5. PubMed ID: 29032282
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological Significance of CD133 and ALDH1 Cancer Stem Cell Marker Expression in Invasive Ductal Breast Carcinoma.
Mansour SF; Atwa MM
Asian Pac J Cancer Prev; 2015; 16(17):7491-6. PubMed ID: 26625750
[TBL] [Abstract][Full Text] [Related]
9. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
[TBL] [Abstract][Full Text] [Related]
10. Ductal carcinoma in situ of the breast: influence of age on diagnostic, therapeutic, and prognostic features. Retrospective study of 812 patients.
Tunon-de-Lara C; André G; Macgrogan G; Dilhuydy JM; Bussières JE; Debled M; Mauriac L; Brouste V; de Mascarel I; Avril A
Ann Surg Oncol; 2011 May; 18(5):1372-9. PubMed ID: 21108045
[TBL] [Abstract][Full Text] [Related]
11. Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy?
McGhan LJ; Pockaj BA; Wasif N; Giurescu ME; McCullough AE; Gray RJ
Ann Surg Oncol; 2012 Oct; 19(10):3264-9. PubMed ID: 22878619
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
13. Histological assessment of breast lesions identified exclusively by magnetic resonance.
O'Connor V; Arena E; Albright J; Brown N; O'Connor R; Chung M; DiNome M; Shamonki J
Am Surg; 2014 Oct; 80(10):944-7. PubMed ID: 25264635
[TBL] [Abstract][Full Text] [Related]
14. Increased N-myc downstream-regulated gene 1 expression is associated with breast atypia-to-carcinoma progression.
Mao XY; Fan CF; Wei J; Liu C; Zheng HC; Yao F; Jin F
Tumour Biol; 2011 Dec; 32(6):1271-6. PubMed ID: 21909787
[TBL] [Abstract][Full Text] [Related]
15. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
17. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
Bofin AM; Lydersen S; Hagmar BM
Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.
Yu BH; Li BZ; Zhou XY; Shi DR; Yang WT
Diagn Pathol; 2018 May; 13(1):36. PubMed ID: 29848352
[TBL] [Abstract][Full Text] [Related]
19. Flat epithelial atypia with and without atypical ductal hyperplasia: to re-excise or not. Results of a 5-year prospective study.
Uzoaru I; Morgan BR; Liu ZG; Bellafiore FJ; Gaudier FS; Lo JV; Pakzad K
Virchows Arch; 2012 Oct; 461(4):419-23. PubMed ID: 22961104
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.
Visscher DW; Frost MH; Hartmann LC; Frank RD; Vierkant RA; McCullough AE; Winham SJ; Vachon CM; Ghosh K; Brandt KR; Farrell AM; Tarabishy Y; Hieken TJ; Haddad TC; Kraft RA; Radisky DC; Degnim AC
Cancer; 2016 Feb; 122(3):378-85. PubMed ID: 26512815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
